Liu et al. introduced a CD71/CD44 dual-aptamer-gemcitabine (CD71-CD44-GEMs) conjugate for treating bladder cancer by co-targeting cancer cells and cancer stem cells (CSCs) [52]. The gene discussed is CD44; the disease is urinary bladder carcinoma.